Review
BibTex RIS Cite

Year 2022, Volume: 25 Issue: 4, 341 - 349, 30.12.2022

Sunaina Banu Lakshmi Puzhankara Madhurya N Kedlaya Jothi M Varghese Venkitachalam Ramanarayanan

https://doi.org/10.7126/cumudj.1110413

Abstract

References

  • 1. Könönen E, Gursoy M, Gursoy UK. Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues. J Clin Med. 2019;8(8):1135. doi:10.3390/JCM8081135
  • 2. Cekici A, Kantarci A, Hasturk H, Dyke TE Van. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000. 2014;64(1):57. doi:10.1111/PRD.12002
  • 3. Bansal P, Singh P, Bey A, Gupta ND. Sclerostin and occlusion: A brief review. J Indian Soc Periodontol. 2015;19(1):11. doi:10.4103/0972-124X.145785
  • 4. Ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90 Suppl 1(SUPPL. 1):31-35. doi:10.2106/JBJS.G.01183
  • 5. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199(6):805-814. doi:10.1084/JEM.20031454
  • 6. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005;36(6):943-947. doi:10.1016/J.BONE.2005.02.019
  • 7. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-543.
  • 8. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-589. doi:10.1086/318811
  • 9. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15(7):928-935. doi:10.1101/GR.3437105
  • 10. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647-2656. doi:10.1002/JBMR.182
  • 11. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152(9):3312-3322. doi:10.1210/EN.2011-0252
  • 12. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588. doi:10.1359/JBMR.081206
  • 13. Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63-75. doi:10.1016/J.BONE.2016.10.019
  • 14. Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury. 2007;38 Suppl 1(SUPPL. 1). doi:10.1016/J.INJURY.2007.02.010
  • 15. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473. doi:10.7326/M18-0850
  • 16. Yu SH, Hao J, Fretwurst T, et al. Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants. Tissue Eng - Part A. 2018;24(21-22):1672-1679. doi:10.1089/ten.tea.2018.0013
  • 17. Witcher PC, Miner SE, Horan DJ, et al. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI insight. 2018;3(11). doi:10.1172/jci.insight.98673
  • 18. Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152-2159. doi:10.1136/ard.2010.132852
  • 19. Yao Y, Kauffmann F, Maekawa S, et al. Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects. Sci Rep. 2020;10(1):1-10. doi:10.1038/s41598-020-73026-y
  • 20. Liu M, Kurimoto P, Zhang J, et al. Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss. J Dent Res. 2018;97(9):1031-1038. doi:10.1177/0022034518766874
  • 21. Chen H, Xu X, Liu M, et al. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 2015;76:141-148. doi:10.1016/j.bone.2015.04.002
  • 22. Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013;28(11):2347-2356. doi:10.1002/jbmr.1984
  • 23. Ren Y, Han X, Ho SP, et al. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. FASEB J. 2015;29(7):2702-2711. doi:10.1096/fj.14-265496
  • 24. Tamplen M, Fowler T, Markey J, Knott PD, Suva LJ, Alliston T. Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation. Head Neck. 2018;40(7):1453-1460. doi:10.1002/hed.25128
  • 25. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1). doi:10.1186/1471-2288-14-43
  • 26. Zhang D, Hu M, Chu T, et al. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. Bone. 2016;87:161-168. doi:10.1016/j.bone.2016.02.005
  • 27. Stolina M, Dwyer D, Niu QT, et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone. 2014;67:305-313. doi:10.1016/j.bone.2014.07.031
  • 28. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-420. https://europepmc.org/article/med/24382002. Accessed May 27, 2021.
  • 29. Allison H, Holdsworth G, McNamara LM. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes. BMC Mol Cell Biol. 2020;21(1). doi:10.1186/s12860-020-00322-w
  • 30. Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113(3):517-525. doi:10.1182/blood-2008-03-145169
  • 31. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24. doi:10.1016/S0169-409X(97)00048-3
  • 32. Bouaziz W, Funck-Brentano T, Lin H, et al. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways. Arthritis Res Ther. 2015;17(1):24. doi:10.1186/s13075-015-0540-6
  • 33. Wehmeyer C, Frank S, Beckmann D, et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330). doi:10.1126/scitranslmed.aac4351

Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review

Year 2022, Volume: 25 Issue: 4, 341 - 349, 30.12.2022

Sunaina Banu Lakshmi Puzhankara Madhurya N Kedlaya Jothi M Varghese Venkitachalam Ramanarayanan

https://doi.org/10.7126/cumudj.1110413

Abstract

Objectives
The use of Sclerostin Antibody(Scl-Ab) as a bone anabolic agent has shown significant benefit in bone disorders in preclinical animal models and human clinical trials. Currently available evidence on the use of Scl-Ab in alveolar bone regeneration is limited to animal studies and hence this scoping review encompasses the animal studies conducted to ascertain the effectiveness of Scl-Ab on alveolar bone regeneration.
Materials and methods
The search strategy was aimed to locate published animal studies in which the treatment arm includes Sclerostin antibody administration for alveolar bone preservation or regeneration. The search terms used were (((Animal model) OR Rodent) AND Alveolar bone defect) AND Anti sclerostin antibody) OR Sclerostin antibody) AND Alveolar bone regeneration) OR Bone regeneration) AND Bone fill.
Results
Of the 559 results from Medline/PubMed, Scopus, Web of Science, Google scholar and additional articles from the references, six were included in the review. Scl-Ab was found to be effective in improving the bone quality and quantity. It was also observed that Scl-Ab was useful in reduced bone density associated with diseases and conditiona affecting osteoblast activity.
Conclusion
The review concluded that Scl-Ab promotes alveolar bone augmentation and improves bone quality without surgical interventions.

Keywords

Alveolar bone Animal model Preclinical model Regeneration Sclerostin Sclerostin Antibody

References

  • 1. Könönen E, Gursoy M, Gursoy UK. Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues. J Clin Med. 2019;8(8):1135. doi:10.3390/JCM8081135
  • 2. Cekici A, Kantarci A, Hasturk H, Dyke TE Van. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000. 2014;64(1):57. doi:10.1111/PRD.12002
  • 3. Bansal P, Singh P, Bey A, Gupta ND. Sclerostin and occlusion: A brief review. J Indian Soc Periodontol. 2015;19(1):11. doi:10.4103/0972-124X.145785
  • 4. Ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90 Suppl 1(SUPPL. 1):31-35. doi:10.2106/JBJS.G.01183
  • 5. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199(6):805-814. doi:10.1084/JEM.20031454
  • 6. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005;36(6):943-947. doi:10.1016/J.BONE.2005.02.019
  • 7. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-543.
  • 8. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-589. doi:10.1086/318811
  • 9. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15(7):928-935. doi:10.1101/GR.3437105
  • 10. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647-2656. doi:10.1002/JBMR.182
  • 11. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152(9):3312-3322. doi:10.1210/EN.2011-0252
  • 12. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588. doi:10.1359/JBMR.081206
  • 13. Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63-75. doi:10.1016/J.BONE.2016.10.019
  • 14. Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury. 2007;38 Suppl 1(SUPPL. 1). doi:10.1016/J.INJURY.2007.02.010
  • 15. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473. doi:10.7326/M18-0850
  • 16. Yu SH, Hao J, Fretwurst T, et al. Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants. Tissue Eng - Part A. 2018;24(21-22):1672-1679. doi:10.1089/ten.tea.2018.0013
  • 17. Witcher PC, Miner SE, Horan DJ, et al. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI insight. 2018;3(11). doi:10.1172/jci.insight.98673
  • 18. Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152-2159. doi:10.1136/ard.2010.132852
  • 19. Yao Y, Kauffmann F, Maekawa S, et al. Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects. Sci Rep. 2020;10(1):1-10. doi:10.1038/s41598-020-73026-y
  • 20. Liu M, Kurimoto P, Zhang J, et al. Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss. J Dent Res. 2018;97(9):1031-1038. doi:10.1177/0022034518766874
  • 21. Chen H, Xu X, Liu M, et al. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 2015;76:141-148. doi:10.1016/j.bone.2015.04.002
  • 22. Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013;28(11):2347-2356. doi:10.1002/jbmr.1984
  • 23. Ren Y, Han X, Ho SP, et al. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. FASEB J. 2015;29(7):2702-2711. doi:10.1096/fj.14-265496
  • 24. Tamplen M, Fowler T, Markey J, Knott PD, Suva LJ, Alliston T. Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation. Head Neck. 2018;40(7):1453-1460. doi:10.1002/hed.25128
  • 25. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1). doi:10.1186/1471-2288-14-43
  • 26. Zhang D, Hu M, Chu T, et al. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. Bone. 2016;87:161-168. doi:10.1016/j.bone.2016.02.005
  • 27. Stolina M, Dwyer D, Niu QT, et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone. 2014;67:305-313. doi:10.1016/j.bone.2014.07.031
  • 28. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-420. https://europepmc.org/article/med/24382002. Accessed May 27, 2021.
  • 29. Allison H, Holdsworth G, McNamara LM. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes. BMC Mol Cell Biol. 2020;21(1). doi:10.1186/s12860-020-00322-w
  • 30. Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113(3):517-525. doi:10.1182/blood-2008-03-145169
  • 31. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24. doi:10.1016/S0169-409X(97)00048-3
  • 32. Bouaziz W, Funck-Brentano T, Lin H, et al. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways. Arthritis Res Ther. 2015;17(1):24. doi:10.1186/s13075-015-0540-6
  • 33. Wehmeyer C, Frank S, Beckmann D, et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330). doi:10.1126/scitranslmed.aac4351
There are 33 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Review
Authors

Sunaina Banu 0000-0002-6893-4630

Lakshmi Puzhankara 0000-0002-5559-5887

Madhurya N Kedlaya 0000-0003-2888-3274

Jothi M Varghese 0000-0002-8503-5039

Venkitachalam Ramanarayanan 0000-0002-5587-3453

Publication Date December 30, 2022
Submission Date May 10, 2022
Published in Issue Year 2022Volume: 25 Issue: 4

Cite

EndNote Banu S, Puzhankara L, Kedlaya MN, Varghese JM, Ramanarayanan V (December 1, 2022) Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review. Cumhuriyet Dental Journal 25 4 341–349.
 Download Cover Image

Cumhuriyet Dental Journal (Cumhuriyet Dent J, CDJ) is the official publication of Cumhuriyet University Faculty of Dentistry. CDJ is an international journal dedicated to the latest advancement of dentistry. The aim of this journal is to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of dentistry. First issue of the Journal of Cumhuriyet University Faculty of Dentistry was published in 1998. In 2010, journal's name was changed as Cumhuriyet Dental Journal. Journal’s publication language is English.


CDJ accepts articles in English. Submitting a paper to CDJ is free of charges. In addition, CDJ has not have article processing charges.

Frequency: Four times a year (March, June, September, and December)

IMPORTANT NOTICE

All users of Cumhuriyet Dental Journal should visit to their user's home page through the "https://dergipark.org.tr/tr/user" " or "https://dergipark.org.tr/en/user" links to update their incomplete information shown in blue or yellow warnings and update their e-mail addresses and information to the DergiPark system. Otherwise, the e-mails from the journal will not be seen or fall into the SPAM folder. Please fill in all missing part in the relevant field.

Please visit journal's AUTHOR GUIDELINE to see revised policy and submission rules to be held since 2020.